A wnaiff y Gweinidog ddatganiad am argaeledd Avastin gan Fyrddau Iechyd Lleol yng Nghymru?
Wedi'i ateb gan Ysgrifennydd y Cabinet dros Iechyd, Llesiant a Chwaraeon | Wedi'i ateb ar 14/07/2016
Avastin® has been appraised by NICE on several occasions. However, on each occasion NICE was unable to recommend the routine use of Avastin® for any of its cancer indications because the manufacturer, Roche, was unable to demonstrate a benefit to patients in balance with the cost.
Where medicines such as Avastin® are not routinely available in NHS Wales, a clinician may apply for the medicine on behalf of their patient by making an Individual Patient Funding Request (IPFR) application.